Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy

American Journal of Medicine

Volumn 104, Issue 3, 1998, Pages 232-237

  Vincent Rajkumar, S ^a   Gertz, Morie A ^a   Kyle, Robert A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN LIGHT CHAIN; SERUM ALBUMIN;

ADULT; AMYLOIDOSIS; ARTICLE; AUTONOMIC NEUROPATHY; BONE MARROW BIOPSY; CLINICAL ARTICLE; ECHOCARDIOGRAPHY; ELECTROMYOGRAPHY; FEMALE; HEART AMYLOIDOSIS; HUMAN; KIDNEY AMYLOIDOSIS; MALE; MUSCLE WEAKNESS; NERVE CONDUCTION; NEUROPATHY; PARESTHESIA; PRIORITY JOURNAL; PROGNOSIS; SURAL NERVE; SURVIVAL RATE;

ACTUARIAL ANALYSIS; AGED; AMYLOID NEUROPATHIES; AMYLOIDOSIS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0032033026     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00037-0     Document Type: Article

References (27)

1. 1. Kyle RA, Gertz MA. Amyloidosis. In: Hoffman R, Benz EJ Jr, Shattil SJ, et al, eds. Hematology: Basic Principles and Practice. 2nd ed. New York: Churchill Livingstone; 1995:1375-1386.
2. 2. De Navasquez S, Treble HA. Case of primary generalized amyloid disease with involvement of nerves. Brain. 1938;61:116-128.
3. 3. Kyle RA, Bayrd ED. Amyloidosis: review of 236 cases. Medicine (Baltimore). 1975;54:271-299.
4. 4. Benson MD, Cohen AS, Brandt KD, Cathcart ES. Neuropathy, M components, and amyloid. Lancet. 1975;1:10-12.
5. 5. Kelly JJ Jr, Kyle RA, O'Brien PC, Dyck PJ. The natural history of peripheral neuropathy in primary systemic amyloidosis. Ann Neurol. 1979;6:1-7.
6. 6. Duston MA, Skinner M, Anderson J, Cohen AS. Peripheral neuropathy as an early marker of AL amyloidosis. Arch Intern Med. 1989; 149:358-360.
7. 7. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
8. 8. Cox DR. Regression models and life-tables. J R Stat Soc (B). 1972; 34:187-202.
9. 9. Christensen E. Multivariate survival analysis using Cox's regression model. Hepatology. 1987;7:1346-1358.
10. 10. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45-59.
11. 11. Kyle RA, Greipp PR, O'Fallon WM. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood. 1986;68:220-224.
12. 12. Kelly JJ Jr. Peripheral neuropathies associated with monoclonal proteins: a clinical review. Muscle Nerve. 1985;8:138-150.
13. 13. Bosch EP, Smith BE. Peripheral neuropathies associated with monoclonal proteins. Med Clin North Am. 1993;77:125-139.
14. 14. Gertz MA, Kyle RA. Primary systemic amyloidosis - a diagnostic primer. Mayo Clin Proc. 1989;64:1505-1519.
15. 15. Traynor AE, Gertz MA, Kyle RA. Cranial neuropathy associated with primary amyloidosis. Ann Neurol. 1991;29:451-454.
16. 16. Kelly JJ Jr. The electrodiagnostic findings in peripheral neuropathy associated with monoclonal gammopathy. Muscle Nerve. 1983;6: 504-509.
17. 17. Kelly JJ Jr, Kyle RA, Miles JM, et al. The spectrum of peripheral neuropathy in myeloma. Neurology. 1981;31:24-31.
18. 18. Thomas PK, King RH. Peripheral nerve changes in amyloid neuropathy. Brain. 1974;97:395-406.
19. 19. Trotter JL, Engel WK, Ignaczak FI. Amyloidosis with plasma cell dyscrasia. An overlooked cause of adult onset sensorimotor neuropathy. Arch Neurol. 1977;34:209-214.
20. 20. Cohen AS, Rubinow A. Amyloid neuropathy. In: Dyck PJ, Thomas PK, Lambert EH, Bunge R, eds. Peripheral Neuropathy. Vol 2, 2nd ed. Philadelphia: WB Saunders; 1984:1866-1898.
21. 21. Greipp PR, Lust JA, O'Fallon WM, et al. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993;81:3382-3387.
22. 22. Kyle RA. Multiple myeloma and other plasma cell disorders. In: Hoffman R, Benz EJ Jr, Shattil SJ, et al, eds. Hematology: Basic Principles and Practice. 2nd ed. New York: Churchill Livingstone; 1995: 1354-1374.
23. 23. Kyle RA, Greipp PR. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood. 1978;52:818-827.
24. 24. Kyle RA, Greipp PR, Garton JP, Gertz MA. Primary systemic amyloidosis: comparison of melphalan/prednisone versus colchicine. Am J Med. 1985;79:708-716.
25. 25. Skinner M, Anderson J, Simms R, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med. 1996;100: 290-298.
26. 26. Gertz MA, Kyle RA. Phase II trial of α-tocopherol (vitamin E) in the treatment of primary systemic amyloidosis. Am J Hematol. 1990;34: 55-58.
27. 27. Gertz MA, Kyle RA. Phase II trial of recombinant interferon alfa-2 in the treatment of primary systemic amyloidosis. Am J Hematol. 1993;44:125-128.